local
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
By By AbbVie at Denton Record-Chronicle
· June 26, 2026
· 1 min read
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritisApproval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kgSKYRIZI…
Why this matters in Denton News
The FDA approval of SKYRIZI for pediatric use in psoriatic disease is a significant development for families in Denton , particularly those with children suffering from moderate-to-severe plaque psoriasis or active psoriatic arthritis. With this approval, local pediatricians and dermatologists will have a new treatment option to offer their young patients, potentially improving their quality of life. The introduction of a new 55 mg pre-filled syringe to support weight-based dosing for patients under 40 kg will also simplify the administration process for healthcare providers in Denton. As the city's healthcare community begins to incorporate SKYRIZI into their treatment protocols, it will be worth watching how this affects the management of psoriatic disease in local pediatric populations, and whether it leads to increased demand for specialized care and support services in the area.
About this story
Original reporting by Denton Record-Chronicle . Denton News surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Denton Record-Chronicle . Have a tip or correction? Contact our newsroom .
Category: local ·
Published: June 26, 2026 ·
Source: Denton Record-Chronicle ·
Reading time: 1 min
Get more Denton News stories like this
Free weekly briefing covering local and other local news. Curated by our editorial team. No spam.
By subscribing you agree to our privacy policy . Unsubscribe anytime.
Frequently asked about this story
What is this story about? SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritisApproval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kgSKYRIZI…
When was this published? This article was first published on June 26, 2026 by Denton Record-Chronicle and curated for Denton News readers.
Who reported this story? This story was reported by By AbbVie at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from Denton News, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter